Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Agreement on profits In the United States
The Swiss pharmaceutical company exceeds expectations with an excellent second quarter. Net sales up 11%, core operating profit up 43%. Strong momentum across all segments, with innovations and expanding pipeline. The company revises upward…
The Swiss big pharma has announced investments in the country to strengthen the production lines, in particular at the Ivrea and Torre Annunziata sites. 100 hires are also expected
Novartis has announced its intention to spin off its Sandoz subsidiary, which specializes in generic medicines, and to list it on the Zurich Stock Exchange and in the United States
Swiss drugmaker continues its pharmaceutical buyouts - This time it's up to the British ocular gene therapy firm to speed up trials for the treatment of geographic atrophy, a leading cause of blindness
Enel Green Power to supply Novartis with 78 MW of renewable energy produced in the Tico wind farm - The pharmaceutical company will be able to avoid the immission of 96.400 tons of CO2 each year
Sparkling corporate deals in the past few hours - Tiffany, Novartis, Charles Schwab and Alibaba's stock market debut in Asia push markets to set records as tariff deal nears
The grand relaunch of the Merger and Acquisition with the big deals of Tiffany and Novartis supports the rise of the markets - But the progress on tariffs and the Hong Kong vote also count
The Swiss giant announced the acquisition for 9,7 billion dollars of the American The Medicine Company, producer of an important drug against cholesterol
The victory of the Democrats in Hong Kong pushes the Asian markets upwards - Two big blows for Lvmh and Novartis: Arnault conquers Tiffany and the Swiss pharmaceutical company offers 7 billion for the American The Medicines
The company sold its 36,5% stake in the Consumer Healthcare joint venture, which deals in non-prescription drugs, including popular and commonly used products, to GlaxoSmithKline
Announced the agreement for the acquisition and subsequent merger between the Swiss group and the American company specialized in genetic therapies for spinal muscular atrophy. Novartis expects to complete the transaction by mid-2018
In a note, the Basel group recalls that since the foundation of Novartis in 1996, the dividend has always increased and represents a payout of 67% on free cash flow.